Mineralys Therapeutics, Inc. (MLYS) stock
MLYSNasdaqPharmaceutical PreparationsFiscal year ends December 31
$13.78−0.70 (-4.83%)
Close on Nov 18, 2026Market cap $1.22BP/E –Yield –
Mineralys Therapeutics cash
Cash and short-term investments held at the end of each period.
Mineralys Therapeutics's cash was $138.27M at Jun 30, 2026. For fiscal 2025 it was $172.92M, up 51.6% from the year before. The highest annual figure on record is $172.92M in fiscal 2025.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $172.92M | +51.6% |
| FY2024 | Dec 31, 2024 | $114.09M | +131.4% |
| FY2023 | Dec 31, 2023 | $49.30M | -43.8% |
| FY2022 | Dec 31, 2022 | $87.70M | +722.6% |
| FY2021 | Dec 31, 2021 | $10.66M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $138.27M | +35.8% |
| Q1 FY2026 | Mar 31, 2026 | $112.78M | -31.7% |
| Q4 FY2025 | Dec 31, 2025 | $172.92M | +51.6% |
| Q3 FY2025 | Sep 30, 2025 | $217.60M | +123.7% |
| Q2 FY2025 | Jun 30, 2025 | $101.79M | +50.0% |
| Q1 FY2025 | Mar 31, 2025 | $165.01M | +82.5% |
| Q4 FY2024 | Dec 31, 2024 | $114.09M | +131.4% |
| Q3 FY2024 | Sep 30, 2024 | $97.27M | +12.7% |
| Q2 FY2024 | Jun 30, 2024 | $67.86M | -32.9% |
| Q1 FY2024 | Mar 31, 2024 | $90.42M | -34.6% |
| Q4 FY2023 | Dec 31, 2023 | $49.30M | -43.8% |
| Q3 FY2023 | Sep 30, 2023 | $86.30M | +76.3% |
| Q2 FY2023 | Jun 30, 2023 | $101.14M | -21.1% |
| Q1 FY2023 | Mar 31, 2023 | $138.25M | +759.7% |
| Q4 FY2022 | Dec 31, 2022 | $87.70M | +722.6% |
| Q3 FY2022 | Sep 30, 2022 | $48.96M | – |
| Q2 FY2022 | Jun 30, 2022 | $128.26M | – |
| Q1 FY2022 | Mar 31, 2022 | $16.08M | – |
| Q4 FY2021 | Dec 31, 2021 | $10.66M | – |
See a number that looks wrong?